Swimming upstream: An advocate reflects on cancer research and social realities

Journal of Clinical Oncology

Volumn 26, Issue 16, 2008, Pages 2783-2786

  Mayer, Musa ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SOCIAL STATUS; ARTICLE; BREAST TUMOR; ECONOMICS; FEMALE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; RESEARCH; TIME; UNITED STATES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG APPROVAL; FEMALE; HUMANS; RESEARCH; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 45749138465     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.4532     Document Type: Short Survey

References (16)

1. US Food and Drug Administration: Patient Involvement. http://www.fda.gov/oashi/patrep/pindex.html
2. Pharmaceutical Research and Manufacturers of America: 2006 Survey: Medicines in Development for Cancer. http://www.phrma.org/files/PhRMA% 20NM%20Cancer%200901.pdf
3. United States Food and Drug Administration: Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Products, 2004. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
4. Abigail Alliance: For Better Access to Developmental Drugs. http://abigail-alliance.org
5. Okie S: Access before approval - A right to take experimental drugs. N Engl J Med 355:437-440, 2006
6. United States Food and Drug Administration: Transcript of the FDA Oncologic Drugs Advisory Committee meeting, Tuesday, September 24, 2002. http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3894T1.htm
7. Lynch TJ: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
8. Press M, Seelig S: Lessons Learned From the Development of a Diagnostic to Predict Response to Herceptin, Targeted Medicine Conference Report, 2004. www.targetedmed.com/flash/lib/pdf/Targeted%20Medicine%20Report.swf
9. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
11. US Food and Drug Administration: Adverse Event Reporting System (AERS). http://www.fda.gov/cder/aers/default.htm
12. The Top Ten Programme: Report on findings and outcomes Prepared for Prof. Mitch Dowsett by Phase IV Communications, 2007, based on Top Ten Priorities in Translational Research. http://www.toptenresearch.org
13. Bazell R: Breast cancer treatment may fail most women. NBC News, June 5, 2007. http://www.msnbc.msn.com/id/19048185/
14. National Breast Cancer Coalition: Press release, NBCCF urges the oncology community to re-assess the use of anthracycline-based chemotherapy in the adjuvant treatment of breast cancer, May 2007. http://www.stopbreastcancer.org/ bin/index.asp? strid=944&btnid=1&depid=20
15. McClellan M: Brookings Institution Conference, 2006. The Practice and Potential of Medicine: How to Close the Gap. http://www.brookings.edu/comm/ events/20061215.htm
16. Woolf SH, Johnson RE, Fryer GE, et al: The health impact of resolving racial disparities: An analysis of us mortality data. Am J Public Health 94:2078-2081, 2004